Blogs

Abstract 5003: Olaparib (Lynparza) combined with abiraterone (Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized phase II trial Conclusion: This is the first trial to show clinical benefit (increase in PFS) for mCRPC pts treated with a PARP inhibitor combined with abiraterone, regardless of HRRm status. Safety data were less favorable for the combination, but no detriment to QoL was seen. The study indicates synergy between olaparib and abiraterone. Abstract 5004:  The

Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the similar outcomes as it does for patients with HER2-positive breast cancer. This is a very important study given that continuation of trastuzumab beyond progression in

Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had received trastuzumab for less time also had fewer heart problems. Out of those who received 6 months of trastuzumab, 4% had to stop the treatment

Last week London had a pretty good weather, slightly chilly evenings and surprisingly, sun-kissed mornings! Yes, we were there to attend the 5th Biennial Biosimilars & Biobetters Congress in London (since the event was in London. I guess it’s a mandate to start with a weather update J) It was a two-day interactive event addressing various topics including market access strategies, clinical development, opportunities and commercial challenges amongst others. However, I will keep it short

Distribution of Anti Pd-1 / Anti PD-L1 by Phase

As the regulatory frameworks for biosimilar development are evolving in both US and EU, more and more biosimilar developers are entering the competitive landscape. Many commercially successful Oncology biologics are going off-patent in next few years, presenting a lucrative opportunity for biosimilar development. The biosimilars pertaining to these biologics constitute the first wave of mAb biosimilars – Avastin®, Herceptin®, and Rituxan®/MabThera®. These 3 Oncology products have a cumulative global sale of over USD 18 billion